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Graphical abstract 
 
Abstract 
Objectives: A systematic review was conducted to evaluate the in vitro effects of nicotine on 
human gingival, periodontal ligament and oral epithelial cells, specifically: cell viability, cell 
attachment, cell proliferation and inflammatory mediator production. 
Materials and Methods:  This report followed the PRISMA statement. Two reviewers 
performed a literature search up to October 2018 in 3 databases: MEDLINE, EMBASE and 
Web of Science, supplemented by manual searching. Inclusion criteria comprised: in vitro 
studies evaluating human gingival fibroblasts, human periodontal ligament cells or human 
gingival/oral epithelial cells; nicotine exposure as a variable; including an appropriate control 
(no nicotine); published in English. Quality assessment was based on a 15-item checklist. 
Results: Of 356 potentially eligible studies, 42 were included. The median quality assessment 
score was 8/15. Study designs were highly heterogeneous. IC50 values for nicotine (exposure 
concentration causing 50% cell death or inhibition of cell growth or other utilised toxicity 
metric) derived from ten studies ranged from 6 μM to 25 mM. Studies investigating cell 
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attachment, proliferation and inflammatory mediator production suggested that effects can be 
seen at a wide range of nicotine concentrations, but results were often contradictory. 
Conclusions: According to findings from in vitro studies, nicotine, at levels found in tobacco 
smokers, nicotine replacement therapy users and e-cigarette users, is unlikely to be cytotoxic 
to human gingival and periodontal cells, though saliva levels in smokeless tobacco users may 
be high enough to achieve cytotoxicity. There was limited and contradictory evidence for 
nicotine effects on cell attachment, proliferation and inflammatory mediator production. 
Clinical Significance: It is well established that whole tobacco smoke is highly damaging to 
oral tissues. The specific effects of nicotine are not well understood but are of increasing 
importance given the recent popularity of novel nicotine products. Increased knowledge on 
this topic will help to better inform dental professionals and patients.  
 
Keywords: Nicotine, Tobacco, Periodontal Diseases, Electronic Cigarettes, Cell Viability.  
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Introduction 
Smoking is highly prevalent in many populations worldwide. The harmful effects of smoking 
on general health have been well documented [1]. Smoking also has significant adverse 
effects on oral health, with a broad literature documenting the relationship of smoking to 
periodontal disease [1-4], wound healing and oral cancers [1].  
Smoking is a major risk factor for periodontitis. Smokers are more likely to suffer from 
periodontitis (OR: 2.14, 95% CI: 1.44-3.17) and tooth loss (OR: 1.5, 95% CI: 1.25-1.81) than 
non-smokers [1]. Smokers have poorer responses to both non-surgical and surgical 
periodontal therapies compared to non-smokers [5-7]. Similarly, it has been shown that 
smokers who quit smoking during periodontal therapy achieve improved clinical outcomes 
compared with those who continue to smoke [8, 9].  
The literature relating to the in vitro effects of tobacco smoke on oral cells and tissues has 
been the subject of two previous review articles [10, 11]. Palmer et al. [11] reviewed the 
potential biological mechanisms underlying the effects of tobacco smoking on periodontitis. 
With regards to nicotine specifically, they concluded that ‘nicotine may be unfairly blamed’ 
for most of the noxious and toxic properties of tobacco smoking. In previous decades, this 
may have been of little consequence, as labelling nicotine as harmful was useful in presenting 
tobacco control public health messages. However, with the more recent availability of 
nicotine replacement therapy (NRT) and new nicotine delivery technologies (such as e-
cigarettes), the specific effects of nicotine on oral tissues and cells is of clear relevance and a 
critical research question.  
To the best of our knowledge there has not been a systematic review conducted on the in 
vitro effects of nicotine on oral and periodontal cells despite the large number of studies 
published. The aim of this systematic review, therefore, was to evaluate the in vitro effects of 
nicotine on human gingival, periodontal ligament and oral epithelial cells, specifically: cell 
viability, cell attachment, cell proliferation and inflammatory mediator production.  
 
Materials and methods 
The PRISMA statement, checklist (Supplementary Figure 1) and flow diagram (Figure 1) 
were utilised in this review. A search protocol was developed a priori following discussion 
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between all members of the research team. The focussed question for the systematic review 
was: In in vitro conditions, does nicotine exposure, compared to no nicotine exposure, lead to 
changes in cell viability, attachment, proliferation or inflammatory mediator production in 
human gingival and periodontal fibroblasts and epithelial cells? This question was 
constructed according to the PICOS framework (Table 1). There is no registration system for 
non-clinical systematic reviews. The review protocol can be obtained by emailing the lead 
author.  
Criteria for considering studies for review  
Inclusion criteria for studies were: (i) primary studies on human gingival fibroblasts (HGFs) 
or human periodontal ligament cells (HPDLCs) or human gingival/oral epithelial cells 
(HGECs/HOECs); (ii) nicotine exposure as a variable; (iii) inclusion of an appropriate control 
(no nicotine); and (iv) published in the English language. Animal studies and abstracts 
without full papers were excluded.  
Search methods for identification of studies 
Electronic searching 
The search terms employed in this study were: ((perio$ [All fields] OR gingiva$ [All fields]) 
AND (fibroblast$ [All fields] OR epithelia$ [All Fields]) AND nicotine). MEDLINE, 
EMBASE and Web of Science were searched without language restriction up to, and 
including 31st October 2018.  
Unpublished data and hand-searching 
Unpublished data were sought by searching a database listing unpublished studies 
(www.opengray.eu). Additionally, reference lists of any potential studies were examined (i.e. 
hand searching) in an attempt to identify any further studies that could be considered for 
inclusion. Bibliographies of review articles, relevant texts, World and European 
Periodontology Workshops were also screened.  A manual search was performed of the 
Journal of Clinical Periodontology (1974-2018), Journal of Periodontology (1944-2018) and 
Journal of Periodontal Research (1966-2018).   
Data collection, extraction and management 
Titles and abstracts from the electronic searches were imported into EndNote X8 (Thomson 
Reuters, New York City, NY, US).  Duplicates were eliminated. Titles were screened 
independently by two reviewers (RH and JC) and those indicating no relevance to this study 
were excluded. Abstracts were then screened independently by two reviewers (RH and JC). 
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The full texts of potentially eligible studies were then reviewed against the 
inclusion/exclusion criteria independently by the two reviewers and disagreement resolved by 
discussion and consultation with the third author (PMP) when necessary. Data were extracted 
independently from the full text articles by two reviewers using a piloted data extraction 
form. Data collected comprised: year of publication, location of first author, funding 
source(s), cell types studied, 15-item Consolidated Standards of Reporting Trials 
(CONSORT) quality assessment, cell viability data (assay used, nicotine exposure conditions 
and results), cell attachment data (assay used, nicotine exposure conditions and results), cell 
proliferation data (assay used, nicotine exposure conditions and results) and inflammatory 
mediator production data (assay used, nicotine exposure conditions and results).  
Assessment of quality in included studies 
A quality assessment was completed on each included study. A 15-item modified CONSORT 
checklist was used [12]. Developed by Faggion [12], this checklist is designed for assessing 
the quality of in vitro pre-clinical research and gives a score out of 15 (with a higher score 
indicating higher quality).  
Data synthesis 
Data were collated into evidence tables, with study characteristics, details of the exposure 
conditions, details of the assays conducted, and quality assessment included. For data 
analysis, a narrative approach was utilised.   
 
Results 
Search results and characteristics of included studies  
The flow chart of manuscripts screened is shown in Figure 1. A total of 356 potentially 
eligible studies were identified by the search strategies. Following removal of duplicates, title 
screening was completed on 292 studies with 192 studies being excluded at this stage. 
Abstract screening was completed on 100 studies with 67 progressing to full-text review. An 
additional three studies were identified from the references of the screened studies. Finally, 
42 studies were included in the full data analysis. Supplementary Table 1 provides reasons 
for exclusion of reviewed full-text studies.  
The characteristics of the included studies are presented in Supplementary Table 2. They 
were published over a 22 year period (1995-2017). Studies were conducted in 13 different 
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countries (based on first author location) with researchers in the USA [13-25], South Korea 
[26-32] and Japan [33-37] publishing the greatest numbers of studies per country.   
Quality assessment 
The median (interquartile range [IQR]) quality assessment score of the 42 assessed papers 
was 8.0 [1.0], out of a maximum possible score of 15. The lowest score was six [38, 39] and 
the highest score was nine [14, 16, 19, 20, 22, 32-37, 40-45]. Regarding the key 
methodological domains assessed by the modified CONSORT checklist, all of the studies 
failed to achieve: sample size determination, random sequence generation, allocation 
concealment, implementation details, blinding and publication of the full study protocol. 
Supplementary Table 3 provides full details of the quality assessment for each study.   
Regarding funding sources for published studies, seven studies did not provide any details 
about funding [13, 18, 24, 39, 46-48], two stated that they had received no funding [26, 41], 
one detailed an individual providing equipment [38], one was funded by a tobacco 
manufacturer [15], one was funded by a tobacco endowment fund [14], and the remainder 
received funding from various educational, governmental and charitable sources 
(Supplementary Table 2). 
Cell types investigated 
The most studied cell type were HGFs, being investigated in 24 studies [13, 14, 19-26, 32-34, 
36, 39-41, 43, 46-51]. Sixteen studies investigated HPDLCs [18-20, 25, 27, 30, 31, 33, 34, 
38, 39, 44, 45, 52-54]. HGECs were investigated by eight studies [15-17, 28, 29, 35, 37, 42], 
with one study using HOECs [50]. Supplementary Table 2 provides details of the origin of 
the cells.  
Nicotine exposure 
Exposure conditions varied among the studies with respect to nicotine concentrations used 
and the duration of exposure.  The nicotine concentrations varied from 1 nM [23, 41] to 100 
mM [48], with a mean (SD) of 4.8 mM (10.9) (median and mode: 1 mM). The exposure time 
varied from 30 minutes [20] to 4 weeks [21] with a mean (SD) of 44.0 hours (54.2) (median 
and mode: 24 hours). Typically, a single dose was administered as diluted pure nicotine 
added to culture medium. Four studies reported subsequent repeat doses of nicotine, all at 24 
hour intervals [13, 39, 40, 46] but only one of these ran a single-dose control [39].  
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Cell viability 
Thirty-three studies investigated cell viability using a range of assays [13, 15-17, 19, 20, 22-
33, 35-37, 39-43, 46-50, 53, 55]. Fifteen studies used the MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay [24, 26-32, 35, 41, 42, 48, 50, 52, 53], five studies 
used the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) assay [16, 17, 19, 20, 43], five studies used the trypan blue assay [23, 33, 39, 
42, 49], two studies used the neutral red assay [40, 46], two studies used microscopic 
observation [13, 22], two study used fluorescent dye assessment [25, 39], one study used the 
sulforhodamine B assay [15], one study used the lactate dehydrogenase leakage assay [47], 
and three studies investigated cell viability in preliminary experiments (but methodological 
details were not provided) [22, 36, 37]. Supplementary Table 4 details the principal results.  
There was significant heterogeneity between studies with respect to nicotine exposure 
conditions. However, 19 studies investigated the effect of a 24-hour exposure of nicotine on 
HGFs [22, 23, 25, 26, 32, 33, 39-41, 43, 46, 48-50] or HPDLCs [25, 27, 30, 31, 33, 39, 52, 
53] (studies explicitly on cells from smokers were excluded in this analysis). Data were 
derived from these studies and all data points combined in Figure 2.   
IC50 
IC50 (defined as the exposure concentration at which there is 50% cell death or inhibition of 
cell growth or other utilised toxicity metric) values were identified from 18 studies reporting 
toxicity data over a range of concentrations for HGFs or HPDLCs [23, 25-27, 30-33, 39-41, 
43, 46, 48-50, 52, 53]  (studies explicitly on cells from smokers were excluded in this 
analysis). One study explicitly reported an ED50 value [39], defining this as ‘effective dose50, 
concentration of a substance which damages 50% of cells irreversibly’. A further nine studies 
[26, 30, 33, 41, 48-50, 52, 53] investigated a sufficient exposure concentration range to allow 
an IC50 value to be derived from the data (Figure 3). Eight studies [23, 25, 27, 31, 32, 40, 43, 
46] did not investigate a sufficient exposure concentration range to allow IC50  determination 
(Figure 3). The IC50 ranged from 6 µM to 25 mM with a mean (SD) of 9.3 mM (8.4 mM). 
Two studies reported values in this range for HGECs; Lee et al. [28] reported an IC50 value of 
300 µM (24 hours) while Gao, Prasad and Zacharias [15] reported that an EC50 (‘effective 
concentration for 50% cytotoxicity’) was not reached with 2.8 mM (24 hours).   
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Cell attachment/adhesion 
Five studies investigated cell attachment/adhesion using a range of assays [21, 38, 41, 51, 
54]. Three studied HGFs [21, 41, 51] and two studied HPDLCs [38, 54] (Supplementary 
Table 4). Four different attachment surfaces were used in the studies: plastic (culture plates) 
[38, 54], root surfaces (from extracted teeth) [21, 41], titanium [51] and glass [21]. Three 
studies used similar nicotine concentrations (620 - 920 nM) and reported similar reductions in 
attachment (approximately 50 - 60%) although they had very different exposure durations: 6 
hours [38], 24 hours [51] and 4 weeks [21].  
Esfahrood et al. [41] reported reduced attachment at a wide range of nicotine concentrations 
(1 nM, 1 µM, 1 mM, 5 mM at 24 h) while James et al. [54] reported an approximately 60% 
reduction in attachment using high nicotine concentrations (31 mM for 24 hours). Both of 
these studies [41, 54] used a viability assay to quantify cells remaining attached to a plate 
under various nicotine exposures, and it is therefore not readily apparent whether viability, 
proliferation or attachment was being measured.  
Cell proliferation 
Eleven studies investigated the effect of nicotine concentration on cell proliferation. Six 
studies investigated nicotine effects on proliferation of HGFs [20, 22, 39, 40, 46, 49], five on 
HPDLCs [18, 20, 38, 39, 53], and two on HGECs [16, 28] (Supplementary Table 4). 
Nine studies reported reductions in cell proliferation [18, 20, 22, 28, 38-40, 46, 53], one of 
which also observed increased cell proliferation at a lower nicotine concentration (2.3 mM, 
24 hours) [18]. Two studies reported inhibition of proliferation at 3.7 mM over 24 hours [40] 
and 48 hours [46], respectively, but no statistically significant inhibition at lower 
concentrations of 37 μM and 370 µM. Ciapetti et al. [46] observed inhibition only after 48 
hours’ exposure, and not at 24 hours. Checchi et al. [40] observed inhibition with 3.7 mM 
over 24 hours; this did not apply to the cells sourced from smoking subjects over 40 years of 
age. Two studies reported no statistically significant effects of nicotine exposure on cell 
proliferation, at respective exposures of 100 nM, 10 μM and 1 mM over 4 and 48 hours [16] 
and 1 μM over 24 to 72 hours [49]. 
Of  five studies [18, 20, 38, 39, 53] which investigated the effect of nicotine on HPDLC  
proliferation, four studies noted inhibitory effects [18, 38, 39, 53], with one study [20] 
reporting that proliferation was not significantly affected (6 or 8 mM; 30 minutes). Chang et 
al. [53] observed dose-dependent inhibition between 25 μM and 200 μM after 96 hours of 
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exposure to nicotine; all proliferation ceased at concentrations above 400 μM. Alpar et al. 
[39] also found dose-dependent inhibition at concentrations above 3.9 mM after 24 hours (all 
proliferation ceased above 31 mM). Only one study reported an increase in cell proliferation 
[18] at 2.3 mM after 24 hours, with inhibition of cell proliferation observed at the higher 
nicotine concentration of 9.2 mM. 
Four studies also investigated cell proliferation indirectly using wound repopulation, or rate 
of artificial wound closure [13, 14, 25, 48]. Three studies used HGFs on culture plates, and 
one used HPDLCs (Supplementary Table 4). Dino et al. [13] reported a significant reduction 
in wound repopulation after 4 days of exposure to 4 mM nicotine, and at 6 days with as little 
as 1 mM nicotine. Lallier et al. [25] reported no effect with up to 1000 μM over 5 days.   
Inflammatory mediator production 
Fifteen studies investigated the effect of nicotine on production of cytokines and other 
inflammatory mediators relevant in the pathogenesis of periodontitis. Seven studies 
investigated the effects on HGFs [22-24, 34, 36, 50, 51], five on HPDLCs [18, 27, 34, 44, 
45], four on HGECs [16, 17, 37, 42], and one on HOECs [50]. The included studies 
investigated between six [24] and one [18, 22, 36, 37, 42, 45] inflammatory mediator(s). The 
most common mediator investigated was interleukin-8 (IL-8) [16, 23, 37, 42, 44, 50, 51] 
followed by interleukin-6 (IL-6) [18, 23, 50, 51], interleukin-1β (IL-1β) [16, 44, 45], 
prostaglandin E2 (PGE2) [16, 27, 36] and interleukin-1α (IL-1α) [16, 17] (Supplementary 
Table 5).  
With respect to IL-8, two studies [17, 50] showed no effect on IL-8 production in HOECs, 
HGECs and HGFs cultures with exposure to a relatively wide range of nicotine 
concentrations (100 nM - 1 mM; 24 hours).  Conversely, five studies [23, 37, 42, 44, 51] 
showed increased IL-8 production in HGFs, HPDLCs and HGECs and ‘stimulated HGECs’ 
cultures with exposure to similar nicotine concentrations (1 nM – 1mM; 24 hours).  
Almasri et al. [56] investigated the expression of 23 inflammatory mediators on the HGF cell 
membrane (rather than production/secretion) and reported that nicotine exposure (1.5 mM, 48 
hours) resulted in the greatest increased expression of growth-regulating oncogene-α (GRO-
α), interleukin-7 (IL-7) and interleukin-15 (IL-15).  
Several studies investigated matrix metalloproteinase (MMP) activity following exposure to 
nicotine. Tipton and Dabbous [22] reported that collagenase activity in HGFs was statistically 
significantly increased by nicotine concentrations ≥ 1.5 mM with a 6-day exposure. Both 
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Zhou et al. [24] and Takeuchi-Igarashi et al. [34] reported that nicotine exposures (both nM 
and mM ranges) had no statistically significant effect on MMP-1 and MMP-2 at time frames 
of up to 48 hours. Kim et al. [27] demonstrated an increase in MMP-2 and MMP-9 (1, 5, 10 
mM nicotine for 24 hours) but no statistical tests were performed.    
Takeuchi-Igarashi et al. [34]  reported significantly increased tissue inhibitors of 
metalloproteinases-1 (TIMP-1) levels (in cell culture supernatants) when cells were exposed 
to nicotine (6.2 nM for 12, 24, and 48 hours) whereas Zhou et al. [24] reported reduced levels 
of TIMP-1 in nicotine-treated cells (1.5 mM, 48 hours, no statistical tests performed).  
 
Discussion 
This systematic review identified a large number of studies that have investigated the in vitro 
effects of nicotine on human gingival, periodontal ligament and oral epithelial cells. We 
observed high heterogeneity between studies particularly regarding the assays performed, the 
cells studied and the nicotine exposure conditions that were applied, the latter being 
particularly varied, with nicotine concentrations ranging from 1 nM [23, 41] to 100 mM [48] 
and exposure time varying from 30 minutes [20] to 4 weeks [21].  
The plasma nicotine concentration of tobacco smokers is well established in the literature 
with reported concentrations usually being in the range of 70 nM to 200 nM [57-65]. Salivary 
nicotine concentrations of tobacco smokers have been reported to range from 4 µM to 10 µM 
[58, 66-68] with much higher levels being reported in smokeless tobacco users (0.43- 9.62 
mM) [69]. Gingival crevicular fluid (GCF) was found to have a nicotine concentration of 37 
µM in an analysis of seven smokers [68]. Plasma nicotine concentrations in those using NRT 
have been shown to be similar to, or lower than, those found in cigarette smokers [62-64, 70]. 
With regards to e-cigarettes, several studies reported little effect on plasma nicotine levels 
[59, 62, 71, 72], most likely because they used early products and novice users. More recent 
studies have reported plasma nicotine concentrations that are similar to those observed in 
tobacco smokers: 100 nM [65, 73] and 300 nM [74]. We are not aware of any published data 
on salivary nicotine concentrations in e-cigarette users, although salivary cotinine levels (a 
metabolite of nicotine) in e-cigarette users have been reported to be similar to those of 
tobacco smokers [75]. A heated tobacco product (heat-not-burn) has been reported to deliver 
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a plasma nicotine concentration of 50 nM [76]. Non-smokers have been reported to have very 
low salivary nicotine concentrations (30 nM) [58].  
It is noteworthy that many of the studies used nicotine concentrations in the mM range and 
these concentrations are only observed in vivo in the saliva of smokeless tobacco users [69].  
The challenge with any in vitro research is to interpret the findings in an appropriate way, 
considering the clinical relevance. For example, when considering cell viability experiments, 
with nicotine concentrations in the regions observed in smokers, NRT users and e-cigarette 
users, no effect on cell viability was observed. This suggests that nicotine is not the cytotoxic 
component of tobacco smoke. Consistent with the findings of an earlier review [10], the 
identified studies in our systematic review only reported a substantial effect on cell viability 
at nicotine concentrations above approximately 5 mM, and such concentrations would only 
be seen in vivo in the saliva of smokeless tobacco users.  From the identified studies, we 
derived the IC50 of nicotine, in HGFs and HPDLCs, and with 24-hour exposure, to range from 
6 µM to 15.6 mM (mean [SD]: 9.3 mM [8.4]). The results of our systematic review therefore 
indicate that the high salivary nicotine concentrations reported in smokeless tobacco users 
can be cytotoxic to gingival and periodontal ligament cells in vitro, as identified in previous 
reviews (although periodontal ligament cells are not usually directly exposed to saliva in 
vivo).  
It should be remembered that pathological processes are more complicated than simple cell 
viability assays and in this review we also looked at studies that reported on cell attachment, 
cell proliferation and inflammatory mediator production. We found that studies reported 
inhibition of cell attachment with exposure to nM concentrations of nicotine whereas cell 
proliferation seemed only to be inhibited by higher concentrations of nicotine (in the µM and 
mM range). Production of inflammatory mediators, including cytokines, appeared to be 
stimulated by exposure to nicotine at a wide range of concentrations (in the nM to mM 
range). However, the identified studies often reported contradictory results, which make it 
hard to draw any definitive conclusions. For example, when considering cell proliferation, for 
an exposure range between 1-5 mM (24 hours), some studies reported inhibitory effects [22, 
39, 40], whilst others reported no effects [16, 46] or even increased proliferation [18].   
It has been postulated by Checchi et al. [40] that some of the differences between studies may 
be accounted for by varied culture or nicotine exposure conditions. They also proposed that 
contradictory findings could result from differences in the cell types studied (for example, 
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whether cells were obtained from smokers or non-smokers, or from younger or older 
individuals, with or without periodontitis, or were commercially-available cell lines, and 
whether the cells were exposed to nicotine after a variable number of passages). It has also 
been suggested than nicotine may have a synergistic action with other substances, for 
example bacterial toxins [77].   
Our quality assessment demonstrated several common deficiencies among the included 
studies. All lacked any randomisation, allocation concealment and blinding, meaning that 
there was a high risk of potential bias. This finding is likely to be true for in vitro studies 
more generally which rarely utilise any of these techniques [78, 79]. When considering 
human studies, the randomised controlled trial is considered to have the most robust study 
design for answering research questions. Similar designs can be utilised for in vitro studies to 
reduce the risk of bias [12, 80]. We also noted that many studies failed to mention any 
limitations of their work. Finally, funding details were absent from a number of the studies, 
which is particularly important given this field of research potentially involving funding from 
the tobacco industry. Only one study openly reported being funded directly by the tobacco 
industry [15], with another funded by a tobacco endowment fund [14].   
There are some limitations of our systematic review. We limited the scope to nicotine and did 
not include cotinine. In vivo, nicotine is metabolised to cotinine which has a longer half-life 
than that of nicotine (11-24 hours compared to 30-150 minutes) meaning that in vivo, cells 
could be exposed to cotinine for longer periods with potentially more detrimental effects. 
Including cotinine was beyond the scope of this review but would be an important 
consideration for future study. We did not attempt to analyse the effect of study heterogeneity 
(e.g. by comparing cells from smokers/non-smokers or from patients with/without 
periodontitis), though the scope for doing this was limited given the variable design of the 
studies that were identified. We limited our systematic review to concentrating on four 
domains (cell viability, attachment, proliferation and inflammatory mediator production) and 
there may be other domains that are important, e.g. cell/bacterial interactions. We also 
included additional information on wound repopulation and cytokine expression. Although 
these were not part of our original inclusion criteria, after evaluating the identified studies we 
felt they offered additional important information and included the data in the relevant 
sections. We were unable to establish in which countries the studies were conducted as this 
was rarely reported. Instead we reported on first author location, accepting this might not 
always be where the study was performed. There is also potential for publication bias e.g. 
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studies which demonstrated no effect of nicotine on the outcome of interest may have been 
less likely to be published.    
In order to improve the quality and value of research in this field and based on the findings of 
this systematic review, we make the following five recommendations for future studies:  
1. Use realistic exposure conditions e.g. nicotine concentrations should ideally be within 
normal physiological ranges or provide justification for why other concentrations are 
used. An example of a study that does this well from the current review is Wendell 
and Stein [23].   
2. Consider using more realistic model systems (e.g. 3D tissue models) rather than the 
classic cell culture monolayers (where appropriate and practical) [81].   
3. Report and consider the influence of cell type and origin e.g. cells from smokers, non-
smokers or unknown. An example of a study that does this well from the current 
review is Checchi et al [40].  
4. Ensure robust study designs, utilising and reporting sample size calculations, 
randomisation, allocation concealment and blinding. Mutahar et al [82] is an example 
of an in vitro study that has utilised some, but not all, of these design features.     
5. Utilise an appropriate reporting guideline or checklist [12, 80] and ensure study 
limitations are discussed and acknowledged and study funding reported.    
 
Conclusions 
From the studies identified in this review, it appears that nicotine at concentrations found in 
the plasma, saliva and GCF of tobacco smokers, NRT users and e-cigarette users is unlikely 
to be cytotoxic to human gingival and periodontal ligament cells in in vitro conditions. 
However, the saliva nicotine concentrations seen in smokeless tobacco users can be cytotoxic 
in these conditions. Evidence of effects on cell attachment, cell proliferation and 
inflammatory mediator production suggested that effects could be seen at a wide range of 
nicotine concentrations but evidence was limited and often contradictory.  
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Figure Legends 
Figure 1 
Title: Flow chart of included and excluded studies (PRISMA) 
 
 
  
S
cr
ee
n
in
g
 
In
cl
u
d
ed
 
E
li
g
ib
il
it
y
 
Id
en
ti
fi
ca
ti
o
n
 
Records after duplicates removed  
(n=64) 
Titles screened  
(n=292) 
Titles excluded  
(n=192) 
Full-text articles 
excluded, with reasons  
(n =28) 
Studies included  
(n=42) 
Abstracts excluded  
(n=21) 
No full-text obtainable 
i.e. conference abstracts 
without full paper  
(n=10) 
No English translation 
obtainable 
(n=2) 
Abstracts screened 
(n=100) 
Records identified through search 
strategy  
(n=356) 
References 
screened, additional 
relevant full-text 
articles assessed  
(n=3) 
 
Full-text articles assessed for 
eligibility  
(n=67) 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
24 
 
Figure 2 
Title: Results of cell viability assays carried out on fibroblast cultures 
Legend: Results of cell viability assays carried out on fibroblast cultures (not reported to be 
from smokers) after 24 h of nicotine exposure; expressed as percentage (of viable cells 
relative to nicotine-free control) on a logarithmic scale of nicotine concentration. Triangles 
represent data points derived from the studies; dotted line represents line of best-fit (Y = -
1.4102 x 10-6 X + 78.926). Normal reported plasma, saliva and gingival crevicular fluid 
nicotine concentrations are shown for comparison with each marker identifying an analysis 
from a study. The corresponding references are: A= [57-65]; B= [57]; C = [62-64, 70]; D= 
[59, 62, 65, 71-74]; E= [76]; F= [58]; G= [58, 66-68]; H= [69]; I= [58, 66]; J= [68]. 
 
Figure 3 
Title: IC50 of fibroblasts exposed to nicotine 
Legend: IC50 of fibroblasts (not reported to be from smokers) after 24 h of nicotine exposure 
(nicotine concentrations at which a 24 h exposure causes fibroblast viability to diminish to 
below 50% relative to nicotine-free control); expressed in millimolar (mM) on a linear scale. 
Squares represent IC50 values and the line/circles represents the range of nicotine 
concentrations used in each study.   
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Tables 
Table 1: Focused research question presented using the PICOS framework. 
PICOS 
Population/patient Human gingival and 
periodontal fibroblasts and 
epithelial cells 
Intervention/indicator Nicotine exposure 
Comparator/control No nicotine exposure 
Outcomes Cell viability 
Cell attachment/adhesion 
Cell proliferation 
Inflammatory mediator 
production  
Study design In vitro, experimental 
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